Literature DB >> 9086154

Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients.

J Odeberg1, Z Yun, A Sönnerborg, K Bjøro, M Uhlén, J Lundeberg.   

Abstract

The viral variability of 5 hepatitis C virus (HCV)-infected immunocompromised patients was analyzed and compared with that in isolates from immunocompetent subjects. The patients were followed longitudinally with regard to changes in hypervariable region 1 (HVR1) of HCV using a direct DNA sequencing approach. For the immunocompromised patients, viral nucleotide sequence variability was markedly lower than in immunocompetent HCV-positive patients. For 1 agammaglobulinemic patient and 1 AIDS patient, no variation in the major amino acid sequence of HCV HVR1 could be observed, while another agammaglobulinemic patient exhibited transient variations and amino acid substitutions despite the lack of functioning humoral immune response. The study supports the general hypothesis of humoral immune selection as the main force of sequence variation in the HVR1 region but suggests that other selection mechanisms may contribute to modulation of the composition of the viral population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9086154     DOI: 10.1086/513995

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Hepatitis G virus infection in Amerindians and other Venezuelan high-risk groups.

Authors:  F H Pujol; Y E Khudyakov; M Devesa; M E Cong; C L Loureiro; L Blitz; F Capriles; S Beker; F Liprandi; H A Fields
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters.

Authors:  J P Allain; Y Dong; A M Vandamme; V Moulton; M Salemi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.

Authors:  J M Pawlotsky; G Germanidis; P O Frainais; M Bouvier; A Soulier; M Pellerin; D Dhumeaux
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy.

Authors:  S C Ray; Y M Wang; O Laeyendecker; J R Ticehurst; S A Villano; D L Thomas
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection.

Authors:  A Manzin; L Solforosi; M Debiaggi; F Zara; E Tanzi; L Romanò; A R Zanetti; M Clementi
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Evolution of hypervariable region 1 of hepatitis C virus in primary infection.

Authors:  A Manzin; L Solforosi; E Petrelli; G Macarri; G Tosone; M Piazza; M Clementi
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.

Authors:  S E Bassett; D L Thomas; K M Brasky; R E Lanford
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants.

Authors:  G Puntoriero; A Meola; A Lahm; S Zucchelli; B B Ercole; R Tafi; M Pezzanera; M U Mondelli; R Cortese; A Tramontano; G Galfre'; A Nicosia
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.